SONX vs. BIOL, XBIO, FWBI, CELZ, PCSA, ENVB, TTNP, LIXT, AVGR, and KA
Should you be buying Sonendo stock or one of its competitors? The main competitors of Sonendo include BIOLASE (BIOL), Xenetic Biosciences (XBIO), First Wave BioPharma (FWBI), Creative Medical Technology (CELZ), Processa Pharmaceuticals (PCSA), Enveric Biosciences (ENVB), Titan Pharmaceuticals (TTNP), Lixte Biotechnology (LIXT), Avinger (AVGR), and Kineta (KA). These companies are all part of the "medical" sector.
Sonendo (NYSE:SONX) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Sonendo has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.
BIOLASE has higher revenue and earnings than Sonendo. Sonendo is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.
BIOLASE has a net margin of -43.56% compared to Sonendo's net margin of -130.16%. Sonendo's return on equity of -150.01% beat BIOLASE's return on equity.
28.7% of Sonendo shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 6.4% of Sonendo shares are owned by company insiders. Comparatively, 0.0% of BIOLASE shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
BIOLASE received 278 more outperform votes than Sonendo when rated by MarketBeat users. Likewise, 55.36% of users gave BIOLASE an outperform vote while only 40.74% of users gave Sonendo an outperform vote.
Sonendo presently has a consensus price target of $1.88, suggesting a potential upside of 1,775.00%. BIOLASE has a consensus price target of $75.20, suggesting a potential upside of 47,285.00%. Given BIOLASE's stronger consensus rating and higher probable upside, analysts plainly believe BIOLASE is more favorable than Sonendo.
In the previous week, BIOLASE had 10 more articles in the media than Sonendo. MarketBeat recorded 13 mentions for BIOLASE and 3 mentions for Sonendo. BIOLASE's average media sentiment score of 0.33 beat Sonendo's score of -1.20 indicating that BIOLASE is being referred to more favorably in the news media.
Summary
BIOLASE beats Sonendo on 11 of the 17 factors compared between the two stocks.
Get Sonendo News Delivered to You Automatically
Sign up to receive the latest news and ratings for SONX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SONX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
